RAREUltragenyx Pharmaceutical Inc.
Pharmaceutical Preparations
- Revenue
- $673M
- 20% YoY
- Operating margin
- -79.5%
- 17% YoY
- EBITDA
- −$500M
- 0.0% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired23% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $351M | $363M | $434M | $560M | $673M | 20% |
| Operating income | −$382M | −$649M | −$569M | −$536M | −$535M | 0.2% |
| Net income | −$454M | −$707M | −$607M | −$569M | −$575M | 1.1% |
| Operating cash flow | −$339M | −$380M | −$475M | −$414M | −$466M | 13% |
| Capex | $73M | $116M | $44M | $7M | $6M | 14% |
| Stock-based comp | $105M | $130M | $135M | $158M | $153M | 3.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $128K · 3
- Net
- −$128K
Pay vs performance
No pay-versus-performance disclosure yet.